Submental fullness, sometimes referred to as “double chin,” is a common, yet undertreated facial aesthetic condition.1It can detract from an otherwise balanced and harmonious facial appearance2 – leading to an older and heavier look.3
Submental fullness can impact a broad range of adults, including both women and men, and can be caused by aging, genetics and weight gain.4
According to a 2015 survey by the American Society for Dermatologic Surgery (ASDS), over 2/3 of consumers are bothered by submental fullness – nearly as many as those bothered by lines and wrinkles around the eyes.5
KYBELLA®is a non-human and non-animal formulation of deoxycholic acid, a naturally-occurring molecule in the body that aids in the breakdown and absorption of dietary fat.7
When injected into subcutaneous fat, KYBELLA®causes the destruction of fat cells. Once destroyed, those cells cannot store or accumulate fat. After the aesthetic response is achieved, retreatment with KYBELLA® is not expected.1
To avoid potential tissue damage, KYBELLA®should not be injected into or in close proximity (1-1.5 cm) to the marginal mandibular nerve, salivary glands, lymph nodes and muscles.
68.2% of subjects treated with KYBELLA®experienced a =1-grade improvement with KYBELLA® compared to 20.5% of placebo-treated subjects, based upon validated physician and patient measurements.*
16% of patients experienced a =2-grade improvement with KYBELLA®, compared to 2% of patients who responded to placebo, based on validated physician and patient measurements
KYBELLA®treatment resulted in high patient satisfaction – 79% of KYBELLA®-treated patients reported satisfaction with their appearance in association with their face and chin.
Patients also reported improvement in the visual and emotional impact of submental fat when asked how happy, bothered, self-conscious, embarrassed, old and overweight they felt following treatment in relation to the amount of their submental fat.
Marginal mandibular nerve (MMN) injury occurred in 4% and dysphagia occurred in 2% of subjects. To avoid potential tissue damage, KYBELLA®should not be injected into or in close proximity (1-1.5 cm) to the MMN, salivary glands, lymph nodes and muscles.
The most common adverse reactions were edema/swelling, hematoma/bruising, pain, numbness, erythema and induration.